Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: An in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice

Miranda D. Grounds, Marilyn Davies, Jo Torrisi, Thea Shavlakadze, Jason White, Stuart Hodgetts

    Research output: Contribution to journalArticle

    44 Citations (Scopus)

    Abstract

    Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many other clinical disorders. We have a specific interest in the treatment of muscle diseases. In order to study the effects of novel anti-cytokine drugs on mouse models of human disease, such drugs must be investigated to determine whether they are indeed effective in blocking the inflammatory response in mouse. This has been carried out by means of a simple in vivo bioassay. Histological examination of transverse sections from whole muscle autografts in C57BL/10ScSn mice sampled at 5 days after transplantation provides an excellent assay model and clearly shows that Remicade and Enbrel block the acute inflammatory cell response in vivo. This graft model has also been used to show that a single intraperitoneal injection of Remicade (10 μg/g) is long-lived and effective when administered at 1 week and even 4 weeks prior to the assay. Enbrel is highly effective when injected twice at -3 days and -1 day (2×100 μg) before muscle grafting but shows no inhibition of the inflammatory response after a single injection (100 μg) 1 week prior to grafting. This striking ablation of inflammation by pharmacological blockage of TNFα is in marked contrast to the lack of any effect in TNFα null mice. This simple reproducible in vivo assay model in mice can be used to evaluate the efficacy of many novel anti-cytokine interventions designed to block inflammation.
    Original languageEnglish
    Pages (from-to)509-515
    Number of pages7
    JournalCell and Tissue Research
    Volume320
    Issue number3
    DOIs
    Publication statusPublished - 01 Jun 2005

    Fingerprint

    Biological Assay
    Tumor Necrosis Factor-alpha
    Cytokines
    Inflammation
    Transplants
    Muscles
    Pharmaceutical Preparations
    Blocking Antibodies
    Tumor Necrosis Factor Receptors
    Autografts
    Intraperitoneal Injections
    Interleukin-1
    Inbred C57BL Mouse
    Chronic Disease
    Therapeutics
    Transplantation
    Etanercept
    Infliximab
    Pharmacology
    Injections

    Cite this

    @article{4e7f620d807a460db4ed798a22ff4a58,
    title = "Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts: An in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice",
    abstract = "Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many other clinical disorders. We have a specific interest in the treatment of muscle diseases. In order to study the effects of novel anti-cytokine drugs on mouse models of human disease, such drugs must be investigated to determine whether they are indeed effective in blocking the inflammatory response in mouse. This has been carried out by means of a simple in vivo bioassay. Histological examination of transverse sections from whole muscle autografts in C57BL/10ScSn mice sampled at 5 days after transplantation provides an excellent assay model and clearly shows that Remicade and Enbrel block the acute inflammatory cell response in vivo. This graft model has also been used to show that a single intraperitoneal injection of Remicade (10 μg/g) is long-lived and effective when administered at 1 week and even 4 weeks prior to the assay. Enbrel is highly effective when injected twice at -3 days and -1 day (2×100 μg) before muscle grafting but shows no inhibition of the inflammatory response after a single injection (100 μg) 1 week prior to grafting. This striking ablation of inflammation by pharmacological blockage of TNFα is in marked contrast to the lack of any effect in TNFα null mice. This simple reproducible in vivo assay model in mice can be used to evaluate the efficacy of many novel anti-cytokine interventions designed to block inflammation.",
    keywords = "Enbrel, Inflammation, Mouse (female C57BL/10SnSc), Muscle, Remicade, TNFα",
    author = "Grounds, {Miranda D.} and Marilyn Davies and Jo Torrisi and Thea Shavlakadze and Jason White and Stuart Hodgetts",
    year = "2005",
    month = "6",
    day = "1",
    doi = "10.1007/s00441-005-1102-z",
    language = "English",
    volume = "320",
    pages = "509--515",
    journal = "Zeitschrift für Zellforschung und mikroskopische Anatomie (Vienna, Austria : 1948)",
    issn = "0302-766X",
    publisher = "Springer-Verlag London Ltd.",
    number = "3",

    }

    Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts : An in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice. / Grounds, Miranda D.; Davies, Marilyn; Torrisi, Jo; Shavlakadze, Thea; White, Jason; Hodgetts, Stuart.

    In: Cell and Tissue Research, Vol. 320, No. 3, 01.06.2005, p. 509-515.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Silencing TNFα activity by using Remicade or Enbrel blocks inflammation in whole muscle grafts

    T2 - An in vivo bioassay to assess the efficacy of anti-cytokine drugs in mice

    AU - Grounds, Miranda D.

    AU - Davies, Marilyn

    AU - Torrisi, Jo

    AU - Shavlakadze, Thea

    AU - White, Jason

    AU - Hodgetts, Stuart

    PY - 2005/6/1

    Y1 - 2005/6/1

    N2 - Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many other clinical disorders. We have a specific interest in the treatment of muscle diseases. In order to study the effects of novel anti-cytokine drugs on mouse models of human disease, such drugs must be investigated to determine whether they are indeed effective in blocking the inflammatory response in mouse. This has been carried out by means of a simple in vivo bioassay. Histological examination of transverse sections from whole muscle autografts in C57BL/10ScSn mice sampled at 5 days after transplantation provides an excellent assay model and clearly shows that Remicade and Enbrel block the acute inflammatory cell response in vivo. This graft model has also been used to show that a single intraperitoneal injection of Remicade (10 μg/g) is long-lived and effective when administered at 1 week and even 4 weeks prior to the assay. Enbrel is highly effective when injected twice at -3 days and -1 day (2×100 μg) before muscle grafting but shows no inhibition of the inflammatory response after a single injection (100 μg) 1 week prior to grafting. This striking ablation of inflammation by pharmacological blockage of TNFα is in marked contrast to the lack of any effect in TNFα null mice. This simple reproducible in vivo assay model in mice can be used to evaluate the efficacy of many novel anti-cytokine interventions designed to block inflammation.

    AB - Dramatic clinical success in the treatment of chronic inflammatory diseases has resulted from the use of anti-cytokine therapies including specific blocking antibodies, soluble receptors and traps to silence the actions of inflammatory cytokines such as tumour necrosis factor alpha (TNFα) and interleukin-1 (IL-1). Two agents used clinically to block the functional activity of TNFα protein are Remicade (an antibody) and Enbrel (a soluble TNF receptor). These tools are now being extended to many other clinical disorders. We have a specific interest in the treatment of muscle diseases. In order to study the effects of novel anti-cytokine drugs on mouse models of human disease, such drugs must be investigated to determine whether they are indeed effective in blocking the inflammatory response in mouse. This has been carried out by means of a simple in vivo bioassay. Histological examination of transverse sections from whole muscle autografts in C57BL/10ScSn mice sampled at 5 days after transplantation provides an excellent assay model and clearly shows that Remicade and Enbrel block the acute inflammatory cell response in vivo. This graft model has also been used to show that a single intraperitoneal injection of Remicade (10 μg/g) is long-lived and effective when administered at 1 week and even 4 weeks prior to the assay. Enbrel is highly effective when injected twice at -3 days and -1 day (2×100 μg) before muscle grafting but shows no inhibition of the inflammatory response after a single injection (100 μg) 1 week prior to grafting. This striking ablation of inflammation by pharmacological blockage of TNFα is in marked contrast to the lack of any effect in TNFα null mice. This simple reproducible in vivo assay model in mice can be used to evaluate the efficacy of many novel anti-cytokine interventions designed to block inflammation.

    KW - Enbrel

    KW - Inflammation

    KW - Mouse (female C57BL/10SnSc)

    KW - Muscle

    KW - Remicade

    KW - TNFα

    UR - http://www.scopus.com/inward/record.url?scp=21244438311&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=21244438311&partnerID=8YFLogxK

    U2 - 10.1007/s00441-005-1102-z

    DO - 10.1007/s00441-005-1102-z

    M3 - Article

    C2 - 15846506

    AN - SCOPUS:21244438311

    VL - 320

    SP - 509

    EP - 515

    JO - Zeitschrift für Zellforschung und mikroskopische Anatomie (Vienna, Austria : 1948)

    JF - Zeitschrift für Zellforschung und mikroskopische Anatomie (Vienna, Austria : 1948)

    SN - 0302-766X

    IS - 3

    ER -